DGAP-News: Cytos Biotechnology Ltd announces the terms and timetable of the rights issue of up to 2,673,796 registered shares for a gross amount of up to CHF 5 million
(firmenpresse) - EquityStory AG-News: Cytos Biotechnology AG / Key word(s): Capital
Increase
Cytos Biotechnology Ltd announces the terms and timetable of the
rights issue of up to 2,673,796 registered shares for a gross amount
of up to CHF 5 million
23.04.2012 / 18:00
---------------------------------------------------------------------
Schlieren (Zurich), Switzerland, April 23, 2012 - Cytos Biotechnology Ltd
('Cytos') announced today the detailed terms and timetable of the capital
increase of up to 2,673,796 registered shares with a nominal value of CHF
0.10 for existing Cytos shareholders, which was approved by Cytos' annual
general meeting last Friday, April 20, 2012. The subscription price for
each new registered share is CHF 1.87.
Shareholders will be offered the right to subscribe for 7 registered shares
for 15 subscription rights, while one subscription right will be allocated
for each existing share. The subscription rights are not tradable.
The following timetable is expected for the capital increase:
- April 23, 2012 Last trading date in existing shares cum rights
- April 24, 2012 First trading date in existing shares ex rights
- April 24, 2012 Start of rights exercise period
- May 10, 2012, 12.00 CEST End of rights exercise period
- May 15, 2012 Listing of shares from rights issue
- May 16, 2012 Payment and settlement
For a detailed description of the capital increase as well as the
recapitalisation of the Company please refer to the offering and listing
prospectus which can be obtained free of charge from Neue Helvetische Bank
AG (phone: +41 44 204 56 19, email: prospectus(at)nhbag.ch) or Cytos
Biotechnology Ltd (phone: +41 44 733 47 47, email: info(at)cytos.com).
For further information please contact:
Cytos Biotechnology Ltd
Harry Welten
Chief Financial Officer
Tel.: +41 44 733 46 46
e-Mail: harry.welten(at)cytos.com
Website: www.cytos.com
About Cytos Biotechnology Ltd
Cytos Biotechnology Ltd is a Swiss public biotechnology company that
specializes in the development and commercialization of a new class of
biopharmaceutical products - the Immunodrugs(TM). Immunodrugs(TM) are
intended for use in the treatment and prevention of common chronic
diseases, which afflict millions of people worldwide. Immunodrugs(TM) are
designed to instruct the patient's immune system to produce the desired
therapeutic antibody or T cell responses that modulate chronic disease
processes. Cytos' Immunodrug(TM) candidates are being developed both
in-house and together with Novartis, Pfizer and Pfizer Animal Health.
Founded in 1995 as a spinoff from the Swiss Federal Institute of Technology
(ETH) in Zurich, the Company is located in Schlieren (Zurich). Cytos
Biotechnology Ltd is listed on the main segment of the SIX Swiss Exchange
Ltd under the symbol CYTN.
This foregoing press release may contain forward-looking statements that
include words or phrases such as 'are intended for', 'are designed to', or
other similar expressions. These forward-looking statements are subject to
a variety of significant uncertainties, including scientific, business,
economic and financial factors, and therefore actual results may differ
significantly from those presented. There can be no assurance that any
further therapeutic entities will enter clinical trials, that clinical
trial results will be predictivefor future results, that therapeutic
entities will be the subject of filings for regulatory approval, that any
drug candidates will receive marketing approval from the U.S. Food and Drug
Administration or equivalent regulatory authorities, or that drugs will be
marketed successfully. Against the background of these uncertainties
readers should not rely on forward-looking statements. The Company assumes
no responsibility to update forward-looking statements or adapt them to
future events or developments.
THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER, OR THE SOLICITATION OF AN
OFFER TO SUBSCRIBE FOR OR PURCHASE ANY SECURITIES TO ANY PERSON IN
AUSTRALIA, CANADA, JAPAN, OR THE UNITED STATES OR IN ANY OTHER
JURISDICTION, NOR DOES IT CONSTITUTE A PROSPECTUS WITHIN THE MEANING OF
ARTICLE 652A OR 1156 OF THE SWISS CODE OF OBLIGATIONS OR A LISTING
PROSPECTUS PURSUANT TO THE LISTING RULES OF THE SIX SWISS EXCHANGE LTD. ANY
DECISION TO PURCHASE ANY SECURITIES REFERRED TO HEREIN SHOULD BE SOLELY
BASED ON THE RELEVANT PROSPECTUS. IN ADDITION, THE OFFER AND SALE OF THE
SECURITIES REFERRED TO HEREIN HAS NOT BEEN AND WILL NOT BE REGISTERED UNDER
THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE 'SECURITIES ACT') OR UNDER
THE APPLICABLE SECURITIES LAWS OF AUSTRALIA, CANADA OR JAPAN. THE
SECURITIES REFERRED TO HEREIN MAY NOT BE OFFERED, SOLD OR DELIVERED WITHIN
THE UNITED STATES ABSENT REGISTRATION UNDER THE SECURITIES ACT OR AN
APPLICABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE
REGISTRATION REQUIREMENTS OF THE SECURITIES ACT. SUBJECT TO CERTAIN
EXCEPTIONS, THE SECURITIES REFERRED TO HEREIN MAY NOT BE OFFERED OR SOLD IN
AUSTRALIA, CANADA OR JAPAN OR TO, OR FOR THE ACCOUNT OR BENEFIT OF, ANY
NATIONAL, RESIDENT OR CITIZEN OF AUSTRALIA, CANADA OR JAPAN. THERE WILL BE
NO PUBLIC OFFER OF THE SECURITIES IN THE UNITED STATES.
IN THE UNITED KINGDOM, THIS PRESS RELEASE IS DIRECTED ONLY AT (I) PERSONS
WHO HAVE PROFESSIONAL EXPERIENCE IN MATTERS RELATING TO INVESTMENTS FALLING
WITHIN ARTICLE 19(1) OF THE FINANCIAL SERVICES AND MARKETS ACT 2000
(FINANCIAL PROMOTION) ORDER 2005 (THE 'ORDER'), AND (II) HIGH NET WORTH
ENTITIES FALLING WITHIN ARTICLE 49(2) OF THE ORDER, AND (III) PERSONS TO
WHOM IT WOULD OTHERWISE BE LAWFUL TO DISTRIBUTE IT.
IN ADDITION, IF AND TO THE EXTENT THAT THIS PRESS RELEASE IS COMMUNICATED
IN, OR THE OFFER OF SECURITIES TO WHICH IT RELATES IS MADE IN, ANY EEA
MEMBER STATE THAT HAS IMPLEMENTED DIRECTIVE 2003/71/EC (TOGETHER WITH ANY
APPLICABLE IMPLEMENTING MEASURES IN ANY MEMBER STATE, THE 'PROSPECTUS
DIRECTIVE'), THIS PRESS RELEASE AND THE OFFERING OF ANY SECURITIES
DESCRIBED HEREIN ARE ONLY ADDRESSED TO AND DIRECTED AT PERSONS IN THAT
MEMBER STATE WHO ARE QUALIFIED INVESTORS WITHIN THE MEANING OF THE
PROSPECTUS DIRECTIVE (OR WHO ARE OTHER PERSONS TO WHOM THE OFFER MAY
LAWFULLY BE ADDRESSED) AND MUST NOT BE ACTED ON OR RELIED ON BY OTHER
PERSONS IN THAT MEMBER STATE.
End of Corporate News
---------------------------------------------------------------------
23.04.2012 News transmitted by EquityStory AG.
The issuer is responsible for the contents of the release.
EquityStory publishes regulatory releases, media releases on the
capital market and press releases.
The EquityStory Group distributes authentic and real-time financial
news for over 1'300 listed companies.
The Swiss news archive can be found at
http://www.equitystory.ch/nachrichten
---------------------------------------------------------------------
Language: English
Company: Cytos Biotechnology AG
Wagistr. 25
8952 Schlieren
Switzerland
Phone: +41 44 733 4747
Fax: +41 44 733 4740
E-mail: info(at)cytos.com
Internet: www.cytos.com
ISIN: CH0011025217, CH0029060735
Swiss Security Number: -
Listed: Freiverkehr in Berlin, München, Stuttgart;
Open Market in Frankfurt; SIX
End of News EquityStory AG News-Service
---------------------------------------------------------------------
166172 23.04.2012
Themen in dieser Pressemitteilung:
cytos-biotechnology-ltd-announces-the-terms-and-timetable-of-the-rights-issue-of-up-to-2
673
796-registered-shares-for-a-gross-amount-of-up-to-chf-5-million
Unternehmensinformation / Kurzprofil:
Datum: 23.04.2012 - 18:00 Uhr
Sprache: Deutsch
News-ID 138071
Anzahl Zeichen: 9513
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 395 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Cytos Biotechnology Ltd announces the terms and timetable of the rights issue of up to 2,673,796 registered shares for a gross amount of up to CHF 5 million"
steht unter der journalistisch-redaktionellen Verantwortung von
Cytos Biotechnology AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
